As for patients with mCRPC, treatment with ¹⁷⁷Lu-PSMA-617 RTL and ¹⁷⁷Lu-PSMA I&T gave better effects and caused fewer adverse effects than third-line treatment.
No takes yet. Share an insight, caveat, or question.
Eyben et al. (2017) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: